BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Regulus Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-14 1:05 pm Purchase | 2021-12-31 | 13G | Regulus Therapeutics Inc. RGLS | BIOTECHNOLOGY VALUE FUND L P | 966,124 9.990% | 261,077 (+37.03%) | Filing |
| 2021-02-12 7:23 pm Purchase | 2020-12-31 | 13G | Regulus Therapeutics Inc. RGLS | BIOTECHNOLOGY VALUE FUND L P | 705,046 9.990% | 495,376 (+236.26%) | Filing |